卡比多巴/左旋多巴(Carbidopa/Levodopa) - 药物靶点：DDC x DRDs_在研适应症：帕金森障碍，帕金森病，脑炎后帕金森病_专利_临床

概要

基本信息

药物类型

小分子化药

别名

AP-CD/LD、AP-CDLD、Carbidopa and Levodopa

+ [62]

靶点

DDC x DRDs

作用机制

DDC抑制剂(DOPA脱羧酶抑制剂)、DRDs拮抗剂(多巴胺受体家族拮抗剂)

治疗领域

神经系统疾病内分泌与代谢疾病其他疾病

在研适应症

帕金森障碍帕金森病脑炎后帕金森病+ [4]

非在研适应症

并发症精神运动障碍安定药恶性综合征+ [1]

原研机构

Merck & Co., Inc.

在研机构

Tatsumi Kagaku Co., Ltd.南京兰铭生物医疗科技有限公司AbbVie LLC

+ [13]

非在研机构

汉都医药Amneal Pharma Europe Ltd.

上海汉都医药科技有限公司

+ [1]

最高研发阶段批准上市

首次获批日期

美国 (1975-05-02),

脑炎后帕金森病继发性帕金森病帕金森病

最高研发阶段(中国)批准上市

特殊审评快速通道 (美国)、孤儿药 (美国)

登录后查看时间轴

关联

169

项与卡比多巴/左旋多巴相关的临床试验

NCT06765668

/ Not yet recruiting临床4期

Open-Label Phase 4 Study of CREXONT® (Carbidopa and Levodopa) Extended Release Capsules in Parkinson's Disease Patients

The primary purpose of this study is to evaluate efficacy and safety of CREXONT under real world conditions in participants with Parkinson disease (PD).

开始日期2025-01-01

申办/合作机构

Impax Laboratories LLC

CTR20244711

/ Active, not recruitingN/A

卡左双多巴缓释片（ 50 mg/200 mg ）在健康参与者中的单剂量、随机、开放、两序列、四周期、完全重复交叉空腹／餐后状态下的生物等效性研究

主要研究目的：评价重庆赛维药业有限公司生产的卡左双多巴缓释片与MSD Sharp & Dohme GmbH持证的卡左双多巴缓释片（商品名：Sinemet®（息宁®））空腹和餐后单次口服给药在中国健康人群中的生物等效性。次要研究目的：评价受试制剂和参比制剂在中国健康成年参与者中的安全性。评价中国健康研究参与者单次空腹/餐后口服受试制剂和参比制剂后的安全性。

开始日期2024-12-25

申办/合作机构

重庆赛维药业有限公司

NCT06785298

/ Recruiting临床2/3期IIT

Clinical Study to Evaluate the Possible Efficacy and Safety of Fexofenadine in Patients with Parkinson's Disease Treated with Conventional Treatment

Parkinson's disease (PD) is a chronic, progressive neurological disorder characterized by both motor and non-motor symptoms. PD is the second most common neurodegenerative disorder after Alzheimer's disease and the most common movement disorder. PD has age-related pathology; it is present in 1-2% of the population over 60 years of age. The disease is characterized by a triad of disordered voluntary motor activity in the form of bradykinesia (slowness of movement) or even akinesia (absence of movement),rigidity and postural instability, and a resting tremor of the hands and less commonly the feet.

开始日期2024-12-10

申办/合作机构

Tanta University

100 项与卡比多巴/左旋多巴相关的临床结果

登录后查看更多信息

100 项与卡比多巴/左旋多巴相关的转化医学

登录后查看更多信息

100 项与卡比多巴/左旋多巴相关的专利（医药）

登录后查看更多信息

817

项与卡比多巴/左旋多巴相关的文献（医药）

2025-03-01·PARKINSONISM & RELATED DISORDERS

Long-term, continuous, subcutaneous levodopa/carbidopa infusion with ND0612 in Parkinson's disease: 3-year outcomes from the open-label BeyoND study

Article

作者: Rudzińska, Monika ; Vasquez, Alberto ; Lopes, Nelson ; Kumar, Rajeev ; Roullet-Solignac, Isabelle ; Case, Ryan ; Muhlack, Siegfried ; Stocchi, Fabrizio ; Isaacson, Stuart ; Aldred, Jason ; Simuni, Tanya ; Taylor, Danette ; Greenberg, Jeffrey ; Azulay, Jean-Philippe ; Antonini, Angelo ; Yardeni, Tami ; Struck, Lynn ; Aralu, Cletus ; Rejdak, Konrad ; Djaldetti, Ruth ; Thomas, Karen ; Poewe, Werner ; Rizova, Yuliya ; Schwarz, Johannes ; Bonuccelli, Ubaldo ; Truong, Daniel ; Pazdera, Ladislav ; Savitt, Joseph ; Flitman, Stephen ; Patel, Neepa ; Gasparoli, Elisabetta ; Klos, Kevin ; Leehey, Maureen ; Ellenbogen, Aaron L. ; Gil, Ramon ; Hauser, Robert A. ; Cutler, Barry ; Hassin-Baer, Sharon ; Durif, Franck ; Espay, Alberto J. ; Bhatia, Perminder ; Defebvre, Luc ; Arkadir, David ; LeWitt, Peter ; Ebersbach, Georg ; Gurevich, Tanya ; Isa, Arnaldo ; Krawczyk, Malgorzata ; Sasson, Nissim ; Milo, Ron ; Kassubek, Jan-Rainer ; Biton, Victor ; Safirstein, Beth ; Klepitskaya, Olga ; Ginsberg, Paul ; Onofrj, Marco ; Yahalom, Gilad ; Danaila, Teodor

INTRODUCTION:

ND0612 is being investigated as a continuous, subcutaneous levodopa/carbidopa infusion, in combination with oral levodopa/carbidopa, for motor fluctuations in Parkinson's disease (PD). One-year data from the ongoing BeyoND study (NCT02726386) showed that the ND0612 regimen was safe and well tolerated and provided a sustained ≥2-h improvement in daily Good ON-time through 12 months of treatment.

METHODS:

We describe 3-year safety and efficacy outcomes for participants who completed 12 months of ND0612 treatment in the core study period and entered the extension phase.

RESULTS:

Of the 214 enrolled participants, 120 completed the core 1-year period, and 114 participants continued into the extension phase. Of these, 95/114 (83.3 %) completed 2 years and 77/114 (67.5 %) completed 3 years of study treatment. Key reasons for discontinuation were treatment-emergent adverse events (TEAEs) (n = 5 and n = 11 after 2 and 3 years, respectively) and withdrawal of consent (n = 9 and n = 5, respectively). TEAEs were reported by 105/114 (92.1 %) participants in Year 1, 77/114 (67.5 %) in Year 2, and 73/95 (76.8 %) in Year 3. While most participants experienced infusion site reactions, these led to discontinuation in only five participants during this extension. At Month 36, the mean reduction in OFF-time from baseline was 2.81 h and the increase in Good ON-time was 2.79 h.

CONCLUSIONS:

Three-year results from this open-label study support the long-term safety, tolerability, and efficacy of ND0612. For participants who entered the extension phase, the high rate of retention supports a favorable benefit-risk ratio of the ND0612 regimen for patients with PD experiencing motor fluctuations.

2025-02-01·EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS

A novel levodopa-carbidopa three-layer gastroretentive tablet for improving levodopa pharmacokinetics

Article

作者: Zhou, Wenhu ; Yan, Peng ; Ding, Jinsong ; Zhao, Xiangcheng ; Zhang, Hailong

The narrow absorption window of levodopa and the significant impact of peripheral decarboxylase are the most limiting factors in maintaining prolonged and smooth plasma concentration in patients with Parkinson's disease (PD). Therefore, this study aims to design a novel gastroretentive carbidopa-levodopa three-layer tablet, which consists of an expansion layer, an immediate-release layer, and a sustained-release layer. The expansion layer rapidly expanded with sufficient structural strength and stayed in the beagle's stomach for more than 10 h, delineating excellent gastric retention effects. The immediate-release layer quickly released the drug and the sustained-release layer maintained a stable drug concentration. Importantly, pharmacokinetic data obtained under fed conditions demonstrated that the duration of efficacy of the three-layer tablets was significantly superior to that of the commercially available product Sinemet® CR, with effective levodopa blood levels remaining for up to 12 h. This is expected to offer more convenient clinical medication options for patients with PD.

2025-02-01·PARKINSONISM & RELATED DISORDERS

Duration of “Good On” time per dose: Immediate-release carbidopa-levodopa vs. extended-release carbidopa-levodopa (IPX203, CREXONT®)

Article

作者: Fernandez, H H ; Hauser, R A ; D'Souza, R ; Fisher, S ; Allard, S ; Jimenez-Shahed, J ; Banisadr, G

BACKGROUND:

For Parkinson's disease patients with motor fluctuations, the duration of benefit per levodopa dose is a key metric that reflects a patient's clinical response.

OBJECTIVE:

Determine the difference in mean durations of "Good On" time per dose of subjects randomized to extended-release carbidopa-levodopa (ER CD-LD; IPX203; CREXONT®) vs. immediate-release (IR) CD-LD in the RISE-PD trial.

METHODS:

"Good On" time per dose was assessed at the end of the IR CD-LD dose adjustment phase (Visit 2/Week 3) and compared to End of Study (Visit 7/EOS) between IPX203 and IR CD-LD groups. In addition, to understand if "Good On" time per dose for IR CD-LD before conversion to IPX203 could impact the magnitude of change in "Good On" time per dose of IPX203 vs. IR CD-LD after conversion, subjects were rank-ordered and divided into quartiles based on their initial "Good On" time per dose optimized IR CD-LD values. Changes in "Good On" time per dose between IPX203 and IR CD-LD groups were then compared for each quartile from Visit 2 to EOS.

RESULTS:

IPX203 increased "Good On" time per dose compared to IR CD-LD by a mean of 1.6 h (p < 0.0001). The mean differences in "Good On" time per dose between IPX203 and IR CD-LD were 1.53h for quartile one, 1.39h for quartile two, 1.83h for quartile three, and 1.56h for quartile four (p < 0.0001 for all quartiles).

CONCLUSION:

IPX203 significantly increased "Good On" time per dose regardless of the duration of "Good On" time per dose observed with IR CD-LD.

207

项与卡比多巴/左旋多巴相关的新闻（医药）

2025-02-10

·Pharmaceutical Technology

FDA approves AbbVie’s Emblaveo for intra-abdominal infections

The therapy will be used in conjunction with metronidazole for adults with complicated intra-abdominal infections. Credit: Studio Romantic/Shutterstock. AbbVie has received US Food and Drug Administration (FDA) approval for Emblaveo (aztreonam and avibactam) to be used in conjunction with metronidazole for people aged 18 and over with complicated intra-abdominal infections (cIAI) and limited treatment options. The approval marks the therapy as the first and only intravenous fixed-dose monobactam/β-lactamase inhibitor combo antibiotic. Emblaveo targets cIAI caused by Gram-negative microorganisms, including Escherichia coli and Klebsiella pneumoniae. The therapy combines the monobactam antibiotic, aztreonam, and the β-lactamase inhibitor, avibactam, which protects against serine β-lactamase hydrolysis and restores activity against bacteria producing Metallo-β-lactamases (MBLs). Previous outcomes related to aztreonam’s safety and efficacy for cIAI treatment support the therapy’s approval. The approval was also backed by the clinical trial outcomes from the Phase III trial, REVISIT, which assessed the therapy’s tolerability, efficacy and safety against serious Gram-negative bacterial infections, including those resistant to multiple drugs. AbbVie research and development executive vice-president and chief scientific officer Roopal Thakkar stated: “As bacteria evolve, industry, government and clinical experts must work together to ensure that the infectious disease community has the tools to advance public health. “We’re proud to offer this important novel treatment option to urgently address the significant threat of antimicrobial resistance.” The US regulator granted fast track status and qualified infectious disease product (QIDP) designation to the therapy in 2019. Its commercial availability in the country is expected in the third quarter of this year. Development of the therapy was a collaborative effort between AbbVie and Pfizer, with the former holding commercialisation rights in Canada and the US, and the latter handling other regions. It also benefited from public-private collaborations, including support from the US Department of Health and Human Services, the Administration for Strategic Preparedness and Response, the Biomedical Advanced Research and Development Authority (BARDA) and the EU’s Innovative Medicines Initiative (IMI) under the COMBACTE-CARE project. This consortium is backed by the COMBACTE pan-European clinical and laboratory networks. In October 2024, the FDA approved AbbVie’s Vyalev for treating motor fluctuations in the adult population with advanced Parkinson’s disease .

上市批准临床3期快速通道合格传染病产品临床结果

2025-02-08

·药时空

艾伯维2024年财报：总营收563.34亿美元，自免和肿瘤业务重回增长（附最新管线）

1月31日，艾伯维公布2024年业绩。首席执行官A. Michael表示：“2024年是艾伯维实现重大突破的一年。我们的增长平台表现卓越，凭借关键监管机构的批准以及极具潜力的数据，我们的研发管线得到了显著提升。同时，通过一系列战略交易，我们的业务也得到了进一步强化。我们将带着强大的发展势头迈向2025年，并预计净收入将超过此前的峰值。这也将是Humira在美国失去专利保护后的第二年。” 一、整体业绩 2024年，艾伯维全年总营收563.34亿美元，较去年增长3.7%。研发投入为127.91亿美元，同比大增66.7%。二、各业务板块及主要产品情况自免业务营收266.82亿美元，增长2.1%，在去年略微下跌后重回增长。肿瘤业务营收65.55亿美元，增长10.8%，同样去年下跌后今年回升。美容业务营收51.76亿美元，下降2.2%。神经科学业务营收89.99亿美元，增长16.6%，不过增速有所放缓。眼科业务营收22.42亿美元，下降7.2%。自免领域：Humira优势减弱，昔日“药王”Humira（阿达木单抗）已上市超22年，累计创造超2000亿美元收入。但因专利到期和生物类似药竞争，自2022年销售额下滑，2024年降至89.93亿美元，下滑速度达37.6%。但Skyrizi和Rinvoq增速超50%。IL - 23单抗Skyrizi（利生奇珠单抗）创收117.18亿美元，增长50.9%；JAK1抑制剂Rinvoq（乌帕替尼）创收59.71亿美元，增长50.4%，二者合计176.89亿美元，远超Humira 。艾伯维2024年全年达成16笔并购及BD交易，其中7笔在自免领域，如收购Nimble、引进明济生物产品、收购Landos Biopharma等。肿瘤领域：Imbruvica（伊布替尼）销售额下滑6.9%至33.47亿美元；Venclexta（维奈克拉）销售额增长12.9%达25.83亿美元；血液肿瘤新产品Epkinly（艾可瑞妥单抗）2024年创收1.46亿美元；FRα ADC药物Elahere（索米妥昔单抗）2024年创造4.79亿美元收入。神经科学领域：精神分裂症药物Vraylar（卡利拉嗪）销售额增长18.4%至32.67亿美元；偏头痛药物Ubrelvy增长23.4%达10.06亿美元、Qulipta增长61.3%达6.58亿美元、Botox增长9.8%达32.83亿美元；帕金森药物Duodopa销售额下降4.6%至4.47亿美元。艾伯维近几年持续收购扩大CNS资产版图，2024年又有多项收购动作。三、管线进展与展望 2025 - 2026年，艾伯维将迎来多项新药/适应症的监管批准、上市申请提交及临床数据读出。经调整，艾伯维预计每股收益将达到12.12 - 12.32美元。重申2029年之前预计保持较高的个位数复合年收入增长率，并对Skyrizi和Rinvoq合并销售额上调预期至310亿美元以上。识别微信二维码，可添加药时空小编请注明：姓名+研究方向！

财报并购生物类似药抗体药物偶联物专利到期

2025-02-06

·Pharmaceutical Technology

Supernus wins FDA approval for Parkinson’s pump on fourth try

Onapgo is approved for adult Parkinson’s patients experiencing motor fluctuations. Credit: Inside Creative House via Getty Images. Supernus Pharmaceuticals has won US approval for its wearable pump Onapgo (apomorphine hydrochloride) to treat symptoms of Parkinson’s disease. Supernus’ regulatory path for Onapgo has been marked by multiple setbacks over nearly five years, with the Food and Drug Administration (FDA) rejecting three prior applications before securing approval. The company acquired Onapgo, previously known as SPN-830, from US WorldMeds in 2020. Soon after, Supernus submitted its first application for FDA review. However, in 2020, the agency issued a refusal-to-file (RTF) letter, determining that the submission was incomplete and not ready for formal review. Supernus resubmitted the application twice, receiving complete response letters (CRLs) both times. The first 2022 rejection required further analysis of the infusion device and drug product, while the most recent CRL, issued in April 2023, cited product quality concerns and deficiencies in the master file for the proprietary pump. The company resubmitted its fourth application in August, leading to the current approval. Onapgo will now be available for adult Parkinson’s disease patients experiencing motor fluctuations. The wearable pump is designed to provide a continuous subcutaneous infusion of Supernus’ apomorphine (Apokyn). The drug is intended for patients experiencing “off” periods, where medication wears off and symptoms return or worsen. The approval is based on a Phase III, 12-week study (NCT02006121) involving 107 patients. Onapgo led to a drop in daily “off” time and an increase in daily good “on” time, defined as periods without dyskinesia and the patient’s global impression of change (PGIC). Supernus plans to launch Onapgo in the second quarter of 2025, supported by a team of specialists, a nurse education programme, and access support services. The approval adds Onapgo to a growing list of infusion-based Parkinson’s treatments. AbbVie ’s Vyalev (foscarbidopa and foslevodopa), a continuous subcutaneous infusion therapy combining prodrugs of carbidopa and levodopa, was approved in October 2024 after three regulatory attempts. The FDA’s initial rejection of Vyalev did not involve efficacy or safety concerns but requested additional information on the pump device. The second rejection followed findings of issues at a third-party manufacturer. AbbVie set a precedent in 2015 with its Parkinson’s disease infusion pump therapy Produodopa (foslevodopa foscarbidopa), sparking innovation in drug delivery systems as companies looked for alternatives for conventional oral treatments.

上市批准临床3期

100 项与卡比多巴/左旋多巴相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	卡比多巴/左旋多巴	N04BA02	-

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
帕金森障碍	日本	Tatsumi Kagaku Co., Ltd.	1993-05-14
帕金森病	美国	Organon & Co.	1975-05-02
脑炎后帕金森病	美国	Organon & Co.	1975-05-02
继发性帕金森病	美国	Organon & Co.	1975-05-02

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
运动失调	临床3期	美国	AbbVie, Inc.	2017-02-09
运动失调	临床3期	芬兰	AbbVie, Inc.	2017-02-09
运动失调	临床3期	希腊	AbbVie, Inc.	2017-02-09
运动失调	临床3期	匈牙利	AbbVie, Inc.	2017-02-09
运动失调	临床3期	意大利	AbbVie, Inc.	2017-02-09
运动失调	临床3期	斯洛伐克	AbbVie, Inc.	2017-02-09
运动失调	临床3期	西班牙	AbbVie, Inc.	2017-02-09
安定药恶性综合征	临床3期	美国	AbbVie, Inc.	2015-10-26
安定药恶性综合征	临床3期	澳大利亚	AbbVie, Inc.	2015-10-26
安定药恶性综合征	临床3期	加拿大	AbbVie, Inc.	2015-10-26

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04380142 (FDA_CDER) 人工标引	临床3期	帕金森病	141	Oral IR carbidopa-levodopa	遞築憲願壓壓顧窪襯構(鹽廠艱選鑰鹹獵衊艱廠) = 淵衊憲獵製壓廠衊範積醖獵淵膚廠簾觸糧繭範 (鑰壓繭齋膚壓糧蓋憲齋, 0.50) 更多	积极	2024-10-16
NCT04380142 (FDA_CDER) 人工标引	临床3期	帕金森病	141	VYALEV	遞築憲願壓壓顧窪襯構(鹽廠艱選鑰鹹獵衊艱廠) = 築蓋衊鏇觸網壓遞鬱鏇醖獵淵膚廠簾觸糧繭範 (鑰壓繭齋膚壓糧蓋憲齋, 0.52) 更多	积极	2024-10-16
NCT04006210 (BouNDless, PRNewswire) 人工标引	临床3期	帕金森病	-	ND0612	淵構廠廠鬱鑰選簾繭網(襯淵遞選鹹簾夢艱鹹簾) = 鏇衊憲窪範齋願鏇壓衊餘膚蓋蓋積願獵壓鹹繭 (鏇鬱蓋鬱衊鹽網醖築鹹 ) 更多	积极	2024-09-30
NCT03670953 (FDA_CDER) 人工标引	临床3期	帕金森病	630	CREXONT	鑰淵蓋鏇鹽餘製窪糧蓋(齋窪鹽觸網網夢獵憲鏇) = 膚糧繭鏇繭選獵餘繭膚齋艱餘醖鹹夢夢顧壓夢 (衊觸糧淵鬱鏇壓襯網鏇 ) 更多	积极	2024-08-07
NCT03670953 (FDA_CDER) 人工标引	临床3期	帕金森病	630	Immediate-release carbidopa-levodopa	鑰淵蓋鏇鹽餘製窪糧蓋(齋窪鹽觸網網夢獵憲鏇) = 遞齋憲糧獵顧遞襯鏇構齋艱餘醖鹹夢夢顧壓夢 (衊觸糧淵鬱鏇壓襯網鏇 ) 更多	积极	2024-08-07
NCT02577523 (Phase 2 study, EAN2024)	临床2期	帕金森病	19	24h ND0612 infusion	願選蓋構選糧憲範網廠(選壓淵夢積獵艱範齋繭) = 73.7% of patients self-reported an improvement (including 36.8% very much/much improved) in their global impression of health on Day 3 簾簾壓鹹簾齋積鬱製遞 (鬱築顧壓醖襯壓積鬱廠 )	积极	2024-06-28
NCT04006210 (Phase 3 study, EAN2024)	临床3期	帕金森病	-	Levodopa/carbidopa infusion (ND0612)	艱廠廠夢觸鬱鬱淵夢齋(鬱夢膚觸選簾蓋鏇製鏇) = Occurrence of adverse events (AEs) and serious AEs were generally consistent across subgroups (age, gender, region, and BMI). Consistent with the data for the full safety population, the most common AEs with ND0612 treatment across all subgroups were infusion site reactions. Overall, no relevant differences between subgroups were observed for AEs of particular interest, including dyskinesia, hallucinations, or falls. 願壓艱鑰構鏇齋壓網餘 (顧鬱獵餘遞鹽鏇鹹築範 )	积极	2024-06-28
EAN2024	N/A	注射部位反应	-	ND0612	鹽構網鹹艱鹽艱醖鹽糧(餘衊繭願築醖糧觸艱蓋) = Most (88.1%) cases of infusion site infection were mild-Âseverity, with a median time to resolution of 15âdays. Infusion site infection led to discontinuation in only 12 (2.9%) patients. 鏇觸淵糧鏇蓋簾構衊糧 (窪製糧構獵顧顧鏇淵窪 )	-	2024-06-28
AAN2024	N/A	帕金森病	-	24-hour ND0612 infusion	範憲糧憲範簾鏇襯構遞(觸範憲範網範願憲構鏇) = 艱膚窪壓鬱蓋壓憲鬱願繭鏇壓獵顧鬱願鹽鹽顧 (醖衊觸鹽廠衊艱鬱憲襯 ) 更多	-	2024-04-09
RISE-PD (AAN2024)	临床3期	帕金森病	630	Immediate-Release Carbidopa-Levodopa (IR CD-LD)	夢網構願簾構壓糧膚憲(觸遞壓鏇醖餘鑰範繭觸) = 衊遞繭簾範製鏇廠鏇廠顧餘鬱衊窪觸醖遞窪淵 (遞願願窪鹽構鹹範鬱糧, 6.0) 更多	积极	2024-04-09
RISE-PD (AAN2024)	临床3期	帕金森病	630	Extended-Release Carbidopa-Levodopa (IPX203)	夢網構願簾構壓糧膚憲(觸遞壓鏇醖餘鑰範繭觸) = 鹽獵淵齋膚壓艱衊廠糧顧餘鬱衊窪觸醖遞窪淵 (遞願願窪鹽構鹹範鬱糧, 3.7) 更多	积极	2024-04-09
NCT04006210 (BouNDless, Literature \| Pubmed \| Lancet Neurol) 人工标引	临床3期	帕金森病	381	ND0612	餘鹽製鬱艱鑰醖鑰淵衊(窪選夢膚鹽構鹹艱鹽壓) = 鹽積鬱夢廠壓鹽憲淵膚醖遞夢製蓋鏇積網齋襯 (蓋餘製蓋鹽鑰齋窪淵選, –0.94 ~ –0.02) 达到更多	积极	2024-03-15
	临床3期	帕金森病	381	levodopa+carbidopa	餘鹽製鬱艱鑰醖鑰淵衊(窪選夢膚鹽構鹹艱鹽壓) = 範齋蓋蓋憲蓋鬱鏇醖鏇醖遞夢製蓋鏇積網齋襯 (蓋餘製蓋鹽鑰齋窪淵選, –2.65 ~ –1.74) 达到更多	积极	2024-03-15